The financial prospects of IDEXX Laboratories have been viewed favorably, despite recent losses and underperformance in the healthcare sector. Many investment firms have trimmed their positions and disposed their stocks, yet others have increased their stake or started new positions in the company. The return on capital and Earnings Per Share (EPS) growth at IDEXX are seen as favorable, although EPS growth has been tracking behind five-year shareholder returns. This has led some to question whether the market could be wrong about the company. Despite facing headwinds from low US clinical visits, the poor performance has not detracted from attention from investors. The company announced disappointing Q2 2024 revenue and lowered their 2024 forecast. Although insiders have been selling shares, institutional shareholders retain control owning 88% of the company's shares. The company's financial health was reaffirmed by a rock-solid balance sheet, and analysts are predicting strong revenue for 2024. However, some have downgraded their rating citing the company as overvalued due to strong recurring revenues from consumables and software.
Idexx Laboratories IDXX News Analytics from Thu, 02 Nov 2023 07:00:00 GMT to Sun, 08 Sep 2024 15:28:20 GMT - Rating 5 - Innovation 4 - Information 8 - Rumor -7
